Ripac New Build – Latest news

Concept design for the Ripac New Build Project has been completed!

𝗔𝗻𝗼𝘁𝗵𝗲𝗿 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗵𝗮𝘀 𝗯𝗲𝗲𝗻 𝗿𝗲𝗮𝗰𝗵𝗲𝗱: The concept design for the new RIPAC-LABOR GmbH New Build [...]

12
Aug

Next milestone in the Ripac-Labor New Build project: ‘the laying of the foundation stone’

Last week, the board members of Dopharma B.V., together with Heiko Rüdiger (CEO RIPAC-LABOR GmbH-Labor), [...]

27
Jun

Dopharma and Ripac-Labor announce Ground-breaking Ceremony for new Autogenous Vaccine Production Facility in Potsdam

Raamsdonksveer, Netherlands / Potsdam, Germany, 28 February 2025 – The Dopharma Group and its fully owned [...]

12
Mar

Ripac New Build – Media Gallery

Laying of the foundation stone

Wednesday, June 18, 2025

Ground-breaking Ceremony

Friday, February 28, 2025

Ripac New Build Newsletter

Follow the journey of the Ripac New Build project.

Name(Required)

First Last

Email(Required)

Follow on LinkedIn

More information

About Ripac-Labor

Ripac-Labor GmbH, a fully owned subsidiary of Dopharma International B.V., specializes in veterinary services and the production of autogenous vaccines for livestock. These customized vaccines provide targeted protection against farm-specific pathogens, offering a crucial tool for disease prevention and control. The expansion of Ripac-Labor’s production capabilities further strengthens the Dopharma group’s position in the European veterinary market.

The company currently employs 48 academic specialists, experienced laboratory technicians, and other well-trained staff.

About the Dopharma Group

Dopharma is a family-owned pharmaceutical company dedicated to producing and supplying high-quality veterinary pharmaceuticals for livestock since 1969. With 95% of its veterinary pharmaceuticals manufactured in-house at its GMP-certified production facilities, Dopharma ensures strict quality control and continuous innovation. The company’s mission is to provide smart, science-driven solutions that support the health and productivity of livestock worldwide.

www.dopharma.com

Media inquiries

For media inquiries which are not available on this site, please contact [email protected].